Related Experiment Video
Updated: Jun 6, 2026
06:18
Chimeric Antigen Receptor T Cell Manufacturing on an Automated Cell Processor
Published on: August 18, 2023
FDA draft guidance on adaptive design clinical trials: Pfizer's perspective
Christy Chuang-Stein1, Mohan Beltangady
1Statistics, Pfizer, Inc., Kalamazoo, Michigan, USA. Christy.j.chuang-stein@pfizer.com
Journal of Biopharmaceutical Statistics
|November 9, 2010
Summary
Pfizer shares insights on the US Food and Drug Administration's 2010 draft guidance for adaptive design clinical trials. The company details its internal efforts since 2005 to implement efficient trial designs, including adaptive approaches.
Area of Science:
- Clinical trial methodology
- Pharmaceutical research and development
- Regulatory science
Background:
- The US Food and Drug Administration (FDA) released draft guidance on adaptive design clinical trials in February 2010.
- Adaptive trial designs have gained significant traction within the pharmaceutical industry due to their potential for efficiency.
- This guidance prompted considerable discussion and interest among stakeholders.
Purpose of the Study:
- To present key feedback and comments from Pfizer regarding the FDA's draft guidance on adaptive design clinical trials.
- To document Pfizer's internal initiatives and progress in promoting efficient clinical trial designs since 2005.
- To highlight the integration of adaptive designs into Pfizer's trial strategies.
Main Methods:
- Review and synthesis of internal comments and feedback from Pfizer employees on the FDA's draft guidance.
- Retrospective analysis of Pfizer's internal journey and strategic implementation of efficient trial designs.
- Examination of the role and adoption of adaptive designs within Pfizer's research and development framework.
Main Results:
- Highlights of specific comments and considerations raised by Pfizer concerning the adaptive trial design guidance.
- Demonstration of Pfizer's long-standing commitment to optimizing clinical trial efficiency through various design strategies.
- Evidence of adaptive designs being a component of Pfizer's evolving approach to clinical trials.
Conclusions:
- Pfizer's engagement with regulatory guidance reflects a proactive approach to adopting innovative trial methodologies.
- The company's internal efforts underscore a strategic focus on enhancing the efficiency and effectiveness of clinical trials.
- Adaptive designs are an integral part of Pfizer's ongoing strategy for efficient trial execution.
Related Concept Videos
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:26FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...